- Home
- CB vs VRTX Comparison
CB vs VRTX Comparison
Compare CB & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CB | VRTX |
|---|---|---|
| Founded | 1985 | 1989 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.9B | 135.6B |
| IPO Year | 1995 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CB | VRTX |
|---|---|---|
| Price | $374.02 | $544.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 32 |
| Target Price | $373.22 | ★ $595.36 |
| AVG Volume (30 Days) | 1.5M | ★ 1.5M |
| Earning Date | 10-20-2026 | 11-02-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | 13.13 | ★ 836.54 |
| EPS | ★ 20.46 | 10.90 |
| Revenue | ★ $59,402,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | N/A | $10.46 |
| Revenue Next Year | $4.16 | $10.53 |
| P/E Ratio | ★ $18.07 | $50.24 |
| Revenue Growth | 6.54 | ★ 46.20 |
| 52 Week Low | $291.03 | $412.27 |
| 52 Week High | $384.26 | $568.67 |
Technical Indicators
Market Signals| Indicator | CB | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.78 | 56.16 |
| Support Level | $317.41 | $461.04 |
| Resistance Level | $384.26 | $561.54 |
| Average True Range (ATR) | 6.07 | 17.67 |
| MACD | 0.19 | 0.86 |
| Stochastic Oscillator | 66.21 | 60.24 |
Price Performance
Historical ComparisonAbout CB Chubb Limited
ACE acquired Chubb in 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in over 50 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).